Zhang S - Search Results

1

Discovery of D-Ring-Contracted Artemisinin as a Potent Hydrophobic Tag for Targeted Protein Degradation.

Qing L, Yu Q, Wang C, Lu X, Yang Y, Chen X, Li X, Min J, Pan W, He H, Zhong H, Zhang S. Qing L, et al. Among authors: zhang s. J Med Chem. 2025 Jan 2. doi: 10.1021/acs.jmedchem.4c02269. Online ahead of print. J Med Chem. 2025. PMID: 39748630

2

Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.

Xu J, Zhao A, Chen D, Wang J, Ma J, Qing L, Li Y, Fang H, He H, Pan W, Zhang S. Xu J, et al. Among authors: zhang s. Eur J Med Chem. 2024 Feb 15;266:116160. doi: 10.1016/j.ejmech.2024.116160. Epub 2024 Jan 18. Eur J Med Chem. 2024. PMID: 38277917

3

Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: A joint view of experiments and simulations.

Qing L, Cheng Z, Xu J, Wang Z, Li Y, Gauthier M, Zhang S, He H. Qing L, et al. Among authors: zhang s. Eur J Med Chem. 2025 Jan 15;282:117065. doi: 10.1016/j.ejmech.2024.117065. Epub 2024 Nov 17. Eur J Med Chem. 2025. PMID: 39580914

4

Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen.

Zhang S, Li Y, Li T, Zhang Y, Li H, Cheng Z, Peng N, Liu Y, Xu J, He H. Zhang S, et al. Among authors: zhang y. J Med Chem. 2022 Feb 24;65(4):3632-3643. doi: 10.1021/acs.jmedchem.1c02037. Epub 2022 Feb 14. J Med Chem. 2022. PMID: 35164509

5

Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.

Zhang S, Qing L, Wang Z, Zhang Y, Li Y, Fang H, Liu Y, He H. Zhang S, et al. Among authors: zhang y. J Med Chem. 2023 Apr 13;66(7):4849-4867. doi: 10.1021/acs.jmedchem.2c02006. Epub 2023 Mar 24. J Med Chem. 2023. PMID: 36961373

6

Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.

He H, Chen R, Wang Z, Qing L, Zhang Y, Liu Y, Pan W, Fang H, Zhang S. He H, et al. Among authors: zhang s, zhang y. Bioorg Chem. 2023 Jul;136:106536. doi: 10.1016/j.bioorg.2023.106536. Epub 2023 Apr 10. Bioorg Chem. 2023. PMID: 37054529

7

Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors.

Zhang S, Zhang Y, Wang Z, Qing L, Fu S, Xu J, Li Y, Fang H, He H. Zhang S, et al. Among authors: zhang y. Eur J Med Chem. 2023 Dec 5;261:115836. doi: 10.1016/j.ejmech.2023.115836. Epub 2023 Oct 8. Eur J Med Chem. 2023. PMID: 37826932

8

Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an in Silico Approach Assisted with the Hole-Electron Analysis.

He H, Wang Z, Peng X, Qing L, Zhang Y, Fu S, Xu J, Li Y, Zhang S. He H, et al. Among authors: zhang s, zhang y. J Med Chem. 2024 Jan 11;67(1):543-554. doi: 10.1021/acs.jmedchem.3c01770. Epub 2024 Jan 2. J Med Chem. 2024. PMID: 38166392

9

Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.

Zuo Y, Long Z, Li R, Le Y, Zhang S, He H, Yan L. Zuo Y, et al. Among authors: zhang s. Eur J Med Chem. 2024 Feb 5;265:116106. doi: 10.1016/j.ejmech.2023.116106. Epub 2023 Dec 29. Eur J Med Chem. 2024. PMID: 38169271

10

Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.

He H, Zhang Y, Xu J, Li Y, Fang H, Liu Y, Zhang S. He H, et al. Among authors: zhang s, zhang y. J Med Chem. 2022 Oct 13;65(19):13158-13171. doi: 10.1021/acs.jmedchem.2c00986. Epub 2022 Sep 29. J Med Chem. 2022. PMID: 36173339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85,265 results

Search Page

Filters